Utku Oflazoglu1, Ahmet Alacacioglu2, Umut Varol2, Yuksel Kucukzeybek2, Tarik Salman2, Halil Taskaynatan2, Yasar Yildiz2, Seray Saray2, M Oktay Tarhan3. 1. Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey. u.oflaz35@gmail.com. 2. Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey. 3. Department of Medical Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.
Abstract
BACKGROUND: Sarcopenia is associated with physical disability, increased post-operative complications, poorer tolerance to chemotherapy, and reduced survival outcome. However, little is known about the changes in body composition during chemotherapy treatment. We aimed to determine whether adjuvant or palliative chemotherapy causes the development of sarcopenia in newly diagnosed cancer patients and to reveal the relationship of sarcopenia with the duration of chemotherapy. METHODS: The study included newly diagnosed cancer patients who underwent curative surgery for primary tumor and also cancer patients who were metastatic at diagnosis. Body composition and handgrip strength were assessed by bio-electric impedance analysis (BIA) and handgrip dynamometer tools, respectively. Measurement tests were performed prior to chemotherapy, in the third and sixth months of chemotherapy. RESULTS: The median age of a total of 276 patients was 57.5 years (range 18-83), and majority of them (55.8%) were women. Among the pre-chemotherapy factors that could be associated with sarcopenia, male gender ≥ 65 years of age, body mass ındex (BMI) < 25, and nutritional risk screening 2002 score < 3 were found to be positively associated with sarcopenia (p < 0.001, p = 0.036, p < 0.001, and p < 0.001, respectively). In the multivariate analysis, male gender (p < 0.001) and BMI < 25 (p = 0.047) were found to be significant. Of 276 patients, 14.5% were sarcopenic prior to chemotherapy. After chemotherapy, 21.4% of them were sarcopenic at the end of the third month and 23.9% were sarcopenic at the end of the sixth month. CONCLUSION: The incidence of sarcopenia was found to be increased with chemotherapy itself and its duration in both non-metastatic and metastatic cancer patients which has to be evaluated in detail in disease-specific prospective and randomized studies.
BACKGROUND:Sarcopenia is associated with physical disability, increased post-operative complications, poorer tolerance to chemotherapy, and reduced survival outcome. However, little is known about the changes in body composition during chemotherapy treatment. We aimed to determine whether adjuvant or palliative chemotherapy causes the development of sarcopenia in newly diagnosed cancerpatients and to reveal the relationship of sarcopenia with the duration of chemotherapy. METHODS: The study included newly diagnosed cancerpatients who underwent curative surgery for primary tumor and also cancerpatients who were metastatic at diagnosis. Body composition and handgrip strength were assessed by bio-electric impedance analysis (BIA) and handgrip dynamometer tools, respectively. Measurement tests were performed prior to chemotherapy, in the third and sixth months of chemotherapy. RESULTS: The median age of a total of 276 patients was 57.5 years (range 18-83), and majority of them (55.8%) were women. Among the pre-chemotherapy factors that could be associated with sarcopenia, male gender ≥ 65 years of age, body mass ındex (BMI) < 25, and nutritional risk screening 2002 score < 3 were found to be positively associated with sarcopenia (p < 0.001, p = 0.036, p < 0.001, and p < 0.001, respectively). In the multivariate analysis, male gender (p < 0.001) and BMI < 25 (p = 0.047) were found to be significant. Of 276 patients, 14.5% were sarcopenic prior to chemotherapy. After chemotherapy, 21.4% of them were sarcopenic at the end of the third month and 23.9% were sarcopenic at the end of the sixth month. CONCLUSION: The incidence of sarcopenia was found to be increased with chemotherapy itself and its duration in both non-metastatic and metastatic cancerpatients which has to be evaluated in detail in disease-specific prospective and randomized studies.
Entities:
Keywords:
Bio-electric impedance analysis; Body composition; Chemotherapy; Incidence; Sarcopenia
Authors: T Cederholm; R Barazzoni; P Austin; P Ballmer; G Biolo; S C Bischoff; C Compher; I Correia; T Higashiguchi; M Holst; G L Jensen; A Malone; M Muscaritoli; I Nyulasi; M Pirlich; E Rothenberg; K Schindler; S M Schneider; M A E de van der Schueren; C Sieber; L Valentini; J C Yu; A Van Gossum; P Singer Journal: Clin Nutr Date: 2016-09-14 Impact factor: 7.324
Authors: Savita Joglekar; Aeen Asghar; Sarah L Mott; Benjamin E Johnson; Anna M Button; Eve Clark; James J Mezhir Journal: J Surg Oncol Date: 2014-12-29 Impact factor: 3.454
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Benjamin H L Tan; Laura A Birdsell; Lisa Martin; Vickie E Baracos; Kenneth C H Fearon Journal: Clin Cancer Res Date: 2009-11-03 Impact factor: 12.531
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: Louise E Daly; Éadaoin B Ní Bhuachalla; Derek G Power; Samantha J Cushen; Karl James; Aoife M Ryan Journal: J Cachexia Sarcopenia Muscle Date: 2018-01-09 Impact factor: 12.910